Literature DB >> 466923

Forecasting individual pharmacokinetics.

L B Sheiner, S Beal, B Rosenberg, V V Marathe.   

Abstract

Often drug dosage may be chosen rationally by use of plasma concentration (CP) as the "therapeutic" end point. The ability to accurately forecast the CP resulting from a dosage regimen is central to choosing that regimen. Tradionally forecasting has been attempted only by accounting for known influences on pharmacokinetics, such as sex, age, and renal disease. One must also adjust for previously observed CPs. Herein, we discuss and explain an approach to both of these tasks, mainly focusing on the latter. The approach balances observed outcomes against prior expectations taking account of observation CP error. For digoxin, use of 1 measured CP, as opposed to none, improves forecast precision for future CPs by 40% (decrement in variance of forecast error), and 2 CPs improve it by 67%. There is also an increase in forecast accuracy (decrement in mean of forecast error) as the number of CPs used increases. After only 2, forecast accuracy and precision are as good as theoretically possible. Moreover, information from CPs is far more valuable for forecasting than that from observable patient features-sex, age, and the like; use of all the latter information does not improve accuracy and precision as much as only 1 CP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466923     DOI: 10.1002/cpt1979263294

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  134 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Anticoagulation therapy advisor: a decision-support system for heparin therapy during ECMO.

Authors:  R L Peverini; M Sale; W D Rhine; L M Fagan; L A Lenert
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1992

3.  Monitoring drug therapy.

Authors:  Thierry Buclin; Verena Gotta; Aline Fuchs; Nicolas Widmer; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

Review 4.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

5.  Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

6.  Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Authors:  Sara Colombo; Thierry Buclin; Matthias Cavassini; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Chantal Csajka
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 7.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

8.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

9.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 10.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.